Temporal Trends and Projected Burden of Bone and Articular Cartilage Malignancies in East Asia: A Systematic Analysis for the Global Burden of Disease Study 2023.

Authors

Karlen Ka Pui Law, Alex Kwan Ho Yau, Henry Chung Ngai Chan, Angela On Kei Lai, Agnes King Yan Lam, Kenney Ki Lee Lau

Published in

Orthopedic research and reviews. Volume 18. Pages 622366. Epub Aug 28, 2026.

Abstract

Malignant neoplasm of bone and articular cartilage (MNBAC) is a rare malignancy associated with substantial premature mortality and disability, particularly among younger populations. Comprehensive, region‑specific assessments in East Asia remain limited despite evolving demographic and epidemiologic patterns. Therefore, this study provides the first East Asia-specific epidemiological assessment of MNBAC with future projections.
Utilizing estimates from the Global Burden of Disease (GBD) 2023 study, we quantified incidence, prevalence, deaths, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) attributable to MNBAC in five East Asian countries and territories from 1990 to 2023, with projections extending to 2050 under multiple foresight scenarios. Data are presented as absolute counts and age-standardized rates with 95% uncertainty intervals.
Between 1990 and 2023, in East Asia, the number of incident cases increased from 9,054 to 29,877. DALYs rose from 256,249 to 615,434. Over the same period, age-standardized incidence rates per 100,000 population increased modestly, death rates declined from 3.60 to 3.09, and DALY rates decreased from 138.61 to 112.04. Projections indicate that continued increases in absolute deaths (38,467 by 2050 under the reference scenario) and DALYs (804,272), with similar or higher estimates under alternative scenarios. In contrast, age‑standardized death and DALY rates are projected to remain broadly stable or decline slightly across scenarios.
The burden of MNBAC in East Asia was increasing, with projections indicating a continuing upward trend through 2050. While declines in age-standardized death and DALYrates suggest improved health outcomes, these metrics do not necessarily reflect substantive changes in healthcare systems. Overall, advancements in population health are unlikely to fully counterbalance the rising MNBAC burden. Targeted treatment strategies focusing on MNBAC, as well as enhancements to registries and data collection, are essential for mitigating future health losses.

PMID:
42683386
Bibliographic data and abstract were imported from PubMed on 02 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.